Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

Abstract:

:CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Population pharmacokinetics analyses were performed using nonlinear mixed-effect modeling on pooled data from 3 clinical studies, and the impact of CPX-351 exposures on efficacy and safety was assessed. The pharmacokinetics of cytarabine and daunorubicin were described using 2-compartment models with linear elimination. None of the evaluated covariates had a clinically significant impact on plasma exposure to total cytarabine or daunorubicin, while bilirubin and formulation showed statistically significant effects on pharmacokinetic parameters of cytarabine and daunorubicin, respectively. In patients with mild/moderate renal impairment or serum bilirubin ≤3 mg/dL, plasma exposures to cytarabine and daunorubicin following CPX-351 were within the variability range for patients with normal kidney function or serum bilirubin levels. Exposure-response analysis demonstrated that better efficacy outcomes were associated with higher CPX-351 exposure quartiles. Early mortality rates in all CPX-351 exposure quartiles were lower vs the 7 + 3 control group, and lower mortality rates were associated with higher exposure quartiles. A trend toward greater frequency of grade 3 treatment-emergent adverse events (but not grade 4/5 events) was observed at higher CPX-351 exposure quartiles. Overall, the population pharmacokinetic analyses indicate no adjustments to the recommended dose and schedule of CPX-351 are warranted for patients with mild/moderate renal impairment or serum bilirubin ≤3 mg/dL. Results from the exposure-response analyses suggest the current CPX-351 regimen provides a favorable risk-benefit profile.

journal_name

J Clin Pharmacol

authors

Wang Q,Banerjee K,Vasilinin G,Marier JF,Gibbons JA

doi

10.1002/jcph.1366

subject

Has Abstract

pub_date

2019-05-01 00:00:00

pages

748-762

issue

5

eissn

0091-2700

issn

1552-4604

journal_volume

59

pub_type

杂志文章
  • Trial treatment length optimization with an emphasis on disease progression studies.

    abstract::Optimal design has been used in the past mainly to optimize sampling schedules for clinical trials. Optimization on design variables other than sampling times has been published in the literature only once before. This study shows, as an example, optimization on the length of treatment periods to obtain reliable estim...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270008329560

    authors: Hennig S,Nyberg J,Hooker AC,Karlsson MO

    更新日期:2009-03-01 00:00:00

  • Caffeine metabolism in premature infants.

    abstract::Caffeine has been used frequently in the treatment and prevention of apnea of prematurity. The metabolism of caffeine depends on the activities of the hepatic enzymes that vary from one infant to another. The objective of this study was to determine the influence of postnatal age (PNA), birth weight (BW), study weight...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/00912700122010500

    authors: al-Alaiyan S,al-Rawithi S,Raines D,Yusuf A,Legayada E,Shoukri MM,el-Yazigi A

    更新日期:2001-06-01 00:00:00

  • The role of TNFalpha in ulcerative colitis.

    abstract::Standard of care for ulcerative colitis involves long-term pharmacotherapy or colectomy. Approximately 20% to 30% of patients eventually require a colectomy because patients either do not respond or cannot tolerate the currently available pharmacotherapies. Advances in our knowledge of the pathophysiology of ulcerativ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1177/0091270007301623

    authors: Sands BE,Kaplan GG

    更新日期:2007-08-01 00:00:00

  • Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.

    abstract::The study was undertaken to develop a pharmacokinetic-pharmacodynamic model to characterize efavirenz-induced neuropsychologic impairment, given preexistent impairment, which can be used for the optimization of efavirenz therapy via Monte Carlo simulations. The modeling was performed with NONMEM 7.2. A 1-compartment p...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.533

    authors: Bisaso KR,Mukonzo JK,Ette EI

    更新日期:2015-11-01 00:00:00

  • Early stopping of aerospace medical trials: application of sequential principles.

    abstract::A two-period, crossover trial was conducted in the hypobaric chamber on human subjects to compare the influence of inflight exercise (experimental) and restricted activity (control) on altitude decompression sickness (DCS) during simulated extravehicular activities. Out of 39 pairs (total of 78 exposures), 4 cases of ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1994.tb02012.x

    authors: Kumar KV,Powell MR,Waligora JM

    更新日期:1994-06-01 00:00:00

  • Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

    abstract::A total of 71 HIV-negative healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg once daily (qd) or atazanavir 300 mg + ritonavir 100 mg qd from study days 1 to 15 with a moderate-fat meal. One hour before breakfast, either omeprazole 40 mg ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270007313392

    authors: Klein CE,Chiu YL,Cai Y,Beck K,King KR,Causemaker SJ,Doan T,Esslinger HU,Podsadecki TJ,Hanna GJ

    更新日期:2008-05-01 00:00:00

  • Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes.

    abstract::The integrated glucose-insulin (IGI) model is a previously published semimechanistic model that describes plasma glucose and insulin concentrations after glucose challenges. The aim of this work was to use knowledge of physiology to improve the IGI model's description of glucose absorption and gastric emptying after t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.602

    authors: Alskär O,Bagger JI,Røge RM,Knop FK,Karlsson MO,Vilsbøll T,Kjellsson MC

    更新日期:2016-03-01 00:00:00

  • A double-blind evaluation of the nocturnal antisecretory effects of anisotropine methylbromide in man. Dose response and duration of action studies.

    abstract::The effects of graded doses of anisotropine methylbromide on nocturanl gastric secretion were investigated in a double-blind crossover study in man. Single doses considerably higher than those usually employed for daytime use in adjunctive therapy of peptic ulcer disease significantly reduced acid secretion without si...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1977.tb04583.x

    authors: Freston JW,Forbes JA

    更新日期:1977-01-01 00:00:00

  • Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment.

    abstract::Due to the prevalence of both gastrointestinal and cardiovascular diseases, it is likely that patients may be coprescribed gastric parietal cell proton pump inhibitors and beta-adrenergic antagonists. Therefore, the objectives of this phase I study were to assess the potential effects of the coadministration of lansop...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/00912700022008856

    authors: Karol MD,Locke CS,Cavanaugh JH

    更新日期:2000-03-01 00:00:00

  • Tissue distribution of diazepam and its metabolite desmethyldiazepam: a human autopsy study.

    abstract::Concentrations of diazepam (DZ) and desmethyldiazepam (DMDZ) were determined quantitatively in the brain, skeletal muscle, heart, liver, lung, fat, adrenal gland, and kidney in 14 autopsied patients who had been treated with DZ or clorazepate (a DMDZ prodrug) during their hospital course. To facilitate interpatient co...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1985.tb02888.x

    authors: Friedman H,Ochs HR,Greenblatt DJ,Shader RI

    更新日期:1985-11-01 00:00:00

  • Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.

    abstract::The pharmacokinetics of dexketoprofen trometamol were evaluated in two studies using healthy volunteers. In the first study, the relative bioavailability of a single oral capsule of dexketoprofen free acid 25 mg or dexketoprofen trometamol 25 mg (given as 37 mg of the trometamol salt) was compared to ketoprofen 50 mg ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Barbanoj MJ,Gich I,Artigas R,Tost D,Moros C,Antonijoan RM,García ML,Mauleón D

    更新日期:1998-12-01 00:00:00

  • The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.

    abstract::The disposition of nalmefene, an opioid antagonist intended for the reversal of opioid-induced respiratory depression, and its primary metabolite nalmefene glucuronide, were characterized in adult volunteers with normal renal function and in patients with end-stage renal disease (ESRD). The effect of hemodialysis on t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1996.tb04179.x

    authors: Matzke GR,Frye RF,Alexander AC,Reynolds R,Dixon R,Johnston J,Rault RM

    更新日期:1996-02-01 00:00:00

  • Assessment of the effect of ofatumumab on cardiac repolarization.

    abstract::Ofatumumab is a human monoclonal antibody that binds to a unique CD20 epitope on the surface of B lymphocytes, resulting in efficient lysis of CD20-expressing cells via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. The potential effect of ofatumumab on cardiac repolarization and ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/jcph.376

    authors: Jewell RC,Laubscher K,Lewis E,Fang L,Gafoor Z,Carey J,McKeown A,West S,Wright O,Sedoti D,Dixon I,Hottenstein CS,Chan G

    更新日期:2015-01-01 00:00:00

  • Nicotinic acid for the treatment of hyperlipoproteinemia.

    abstract::Nicotinic acid is a water-soluble B-complex vitamin that has been shown, in high doses, to lower total plasma cholesterol (C), LDL-C, and VLDL-triglycerides (Tg), while raising HDL-C in patients with type II, III, IV, and V hyperlipoproteinemia. Its exact mechanism of action is not known, but it appears to lower the p...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1991.tb03750.x

    authors: Drood JM,Zimetbaum PJ,Frishman WH

    更新日期:1991-07-01 00:00:00

  • Once-daily trandolapril compared with the twice-daily formulation in the treatment of mild to moderate essential hypertension: assessment by conventional and ambulatory blood pressures.

    abstract::A double-blind, crossover study was carried out to compare the antihypertensive efficacy of the long-acting ACE inhibitor trandolapril 1 mg administered once daily and 0.5 mg twice daily in 31 patients with mild to moderate essential hypertension. After randomization, patients entered a single-blind placebo period of ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1993.tb01959.x

    authors: Poirier L,Bourgeois J,Lacourcière Y

    更新日期:1993-09-01 00:00:00

  • Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method.

    abstract::Several approaches are available to estimate the glomerular filtration rate (GFR) from the sinistrin clearance. To compare such approaches, GFR was estimated in six healthy volunteers, both after a bolus injection and a bolus dose followed by a 6-hour infusion. A recently developed high-performance liquid chromatograp...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1997.tb04355.x

    authors: Buclin T,Pechère-Bertschi A,Séchaud R,Décosterd LA,Munafo A,Burnier M,Biollaz J

    更新日期:1997-08-01 00:00:00

  • Biological activity of cannabichromene, its homologs and isomers.

    abstract::Cannabichromene (CBC) is one of four major cannabinoids in Cannabis sativa L. and is the second most abundant cannabinoid in drug-type cannabis. Cannabichromene and some of its homologs, analogs, and isomers were evaluated for antiinflammatory, antibacterial, and antifungal activity. Antiinflammatory activity was eval...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1981.tb02606.x

    authors: Turner CE,Elsohly MA

    更新日期:1981-08-01 00:00:00

  • Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy.

    abstract::The primary objective of this phase 1, open-label, multicenter, 3-period, fixed-sequence study was to evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of digoxin, a probe P-glycoprotein (P-gp) substrate, in patients with BRAFV600 mutation-positive metastatic malignancy. Fol...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1111

    authors: Zhang W,McIntyre C,Kuhn M,Forbes H,Kim TM,Lee J,Demidov L,Colburn D

    更新日期:2018-08-01 00:00:00

  • Estimation of Attainment of Steady-State Conditions for Compounds With a Long Half-Life.

    abstract::Half-life is a standard result reported with analysis of pharmacokinetic data. Different definitions such as noncompartmental half-life, terminal half-life, effective half-life, and context-sensitive half-life can yield substantially different estimates of the quantity "half-life." Time to attainment of steady-state c...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1701

    authors: Krause A,Lott D,Dingemanse J

    更新日期:2021-01-01 00:00:00

  • Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.

    abstract::Long-term prolactin excess is often accompanied by numerous metabolic complications. No previous study has compared the effect of statin therapy on circulating levels of cardiometabolic risk factors in patients with elevated and normal prolactin levels. The study population consisted of 3 age-, weight-, and lipid-matc...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1301

    authors: Krysiak R,Szkróbka W,Okopień B

    更新日期:2019-01-01 00:00:00

  • A bioequivalence study of oral controlled-release morphine using naltrexone blockade.

    abstract::Twenty-three normal volunteers who received morphine sulphate (MS Contin) with naltrexone completed this randomized, analytically blinded, two-way crossover comparison of the bioavailability of one 200-mg oral controlled-release morphine sulfate tablet with two 100-mg MSC tablets. Morphine effects were blocked by thre...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1995.tb04094.x

    authors: Kaiko RF,Grandy RP,Reder RF,Goldenheim PD,Sackler RS

    更新日期:1995-05-01 00:00:00

  • Pharmacodynamic comparison of L-bunolol with propranolol, metoprolol, and placebo.

    abstract::Twelve healthy volunteers received single oral doses of propranolol (80 mg), metoprolol (100 mg), L-bunolol (2 mg), and placebo in a four-way crossover study. Blood pressure, ventricular rate, and echocardiographically determined ejection fraction, ejection time, and mean rate of circumferential fiber shortening (mVcf...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1988.tb05723.x

    authors: Ochs HR,Bahrmann H,Greenblatt DJ,Labedzki L

    更新日期:1988-12-01 00:00:00

  • Tissue penetration of cefpodoxime and cefixime in healthy subjects.

    abstract::Microdialysis is a technique that allows the measurement of free antibiotic concentrations in different tissues, which are responsible for the antibacterial activity at the infection site. In an open, randomized, 2-way crossover study in healthy volunteers, the muscle penetration of orally administered cefpodoxime (40...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/0091270004273679

    authors: Liu P,Müller M,Grant M,Obermann B,Derendorf H

    更新日期:2005-05-01 00:00:00

  • The effect of antacid and ranitidine on droxicam pharmacokinetics.

    abstract::Droxicam is a nonsteroidal anti-inflammatory drug that is a pro-drug of piroxicam. The influence of concomitant administration of antacid or ranitidine on droxicam pharmacokinetics has been investigated. On three separate phases, 15 healthy volunteers received a single oral 20-mg dose of droxicam either alone, with an...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:

    authors: Bartlett A,Costa A,Martínez L,Roser R,Sagarra R,Sánchez J

    更新日期:1992-12-01 00:00:00

  • Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers.

    abstract::An open-label, randomized, crossover study was performed in healthy male volunteers to evaluate the potential pharmacokinetic and pharmacodynamic interactions and tolerability of single oral doses of modafinil (200 mg) and dextroamphetamine (10 mg). Blood samples were collected for determination of plasma levels of mo...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1998.tb04395.x

    authors: Wong YN,Wang L,Hartman L,Simcoe D,Chen Y,Laughton W,Eldon R,Markland C,Grebow P

    更新日期:1998-10-01 00:00:00

  • Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.

    abstract::Inflammatory conditions, such as rheumatoid arthritis, reduce response to calcium channel and beta-adrenergic antagonists but not the angiotensin II type 1 receptor (AT(1)R) antagonist valsartan. Inflammation also reduces clearance of some drugs or active metabolite, thereby reducing response. Active (n = 14) and cont...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/0091270006292163

    authors: Daneshtalab N,Lewanczuk RZ,Russell AS,Jamali F

    更新日期:2006-11-01 00:00:00

  • Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.

    abstract::This study was performed to estimate the population pharmacokinetic (PK) parameters of etanercept in pediatric juvenile rheumatoid arthritis (JRA) patients and to compare the steady-state time-concentration profiles between etanercept 0.8-mg/kg once-weekly and 0.4-mg/kg twice-weekly subcutaneous (SC) regimens by clini...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270004271945

    authors: Yim DS,Zhou H,Buckwalter M,Nestorov I,Peck CC,Lee H

    更新日期:2005-03-01 00:00:00

  • Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms.

    abstract::Propiverine extended release is expected to be better tolerated compared to immediate release tablets because of slower drug release and reduced formation of active metabolites in the colon. CYP3A4 and ABCC2, the major variables in pharmacokinetics of propiverine, are less expressed in the colon. Therefore, dispositio...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270008315314

    authors: May K,Westphal K,Giessmann T,Wegner D,Adam U,Lerch MM,Oertel R,Warzok RW,Weitschies W,Braeter M,Siegmund W

    更新日期:2008-05-01 00:00:00

  • Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation.

    abstract::The pharmacokinetics and pharmacodynamics of flunisolide were studied in healthy volunteers after inhalation. In the morning on the day the study began, volunteers inhaled 0.5 mg of flunisolide with and without oral administration of charcoal, or 1 mg, 2 mg, and 3 mg of flunisolide with concomitant administration of c...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1997.tb04263.x

    authors: Möllmann H,Derendorf H,Barth J,Meibohm B,Wagner M,Krieg M,Weisser H,Knöller J,Möllmann A,Hochhaus G

    更新日期:1997-10-01 00:00:00

  • Comparison of the stability, efficacy, and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation.

    abstract::Recently, a new latanoprost ophthalmic solution containing cyclodextrins was developed. The purpose of the present work was to compare the stability, clinical efficacy, and adverse effect profile of this formulation with the innovator product. The innovator formulation was stable at 4 degrees C but exhibited degradati...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/0091270006292626

    authors: Gonzalez JR,Baiza-Duran L,Quintana-Hau J,Tornero-Montaño R,Castaneda-Hernandez G,Ortiz M,Alarcon-Oceguera F,Beltran-Loustaunau M,Cortez-Gastelum M,Garcidueñas-Mejia J,Gomez-Bastar P,Jimenez-Roman J,Korder-Ortega V,Paczka-Zapata

    更新日期:2007-01-01 00:00:00